Florida Cancer Specialists Identifies Gaps in Lung Cancer Biomarker Testing

Event summary

  • Florida Cancer Specialists' MYLUNG Protocol 2 study highlights progress and gaps in biomarker testing for non-small cell lung cancer (NSCLC) in community settings.
  • The study, published in the Journal of Clinical Oncology, analyzed patterns in biomarker testing and treatment decision-making for newly diagnosed NSCLC patients.
  • FCS aims to track up to 12,000 patients through the MYLUNG Consortium initiative, which engages leading oncology practices, researchers, and industry partners.
  • FCS President Lucio N. Gordan emphasizes the importance of expanding genomic testing capabilities to ensure timely and accurate testing for all patients.

The big picture

Florida Cancer Specialists' study underscores the ongoing shift towards precision oncology in community cancer care. The findings highlight the need for improved workflows and access to ensure all patients benefit from comprehensive genomic profiling. As the MYLUNG Consortium continues to expand, its real-world evidence could set new standards for biomarker testing and treatment decision-making in NSCLC.

What we're watching

Testing Efficiency
Whether FCS can sustain improvements in biomarker testing workflows to ensure all patients receive complete results before starting treatment.
Research Expansion
The pace at which MYLUNG Protocol 3 will explore and implement interventions to enhance biomarker testing effectiveness.
Industry Collaboration
How the MYLUNG Consortium's real-world evidence will influence broader strategies to enhance personalized care delivery and improve outcomes for lung cancer patients.

Related topics

Oncology